Artificial Lung Devices Market Overview
The Artificial Lung Devices Market is expanding as healthcare systems respond to the rising prevalence of respiratory disorders, an aging population, and growing demand for advanced respiratory-support technologies. Technological advances such as device miniaturization, artificial-intelligence-assisted monitoring, improved biocompatibility, and portable systems are supporting market development. The increasing adoption of home healthcare and remote monitoring is also creating new opportunities for artificial lung device manufacturers.
The market was valued at approximately USD 2.1 billion in 2024 and is expected to rise from USD 2.3 billion in 2025 to USD 4.5 billion by 2035, registering a 7.1% CAGR during 2026–2035. North America is the leading regional market, valued at USD 1.2 billion in 2024 and projected to reach USD 2.4 billion by 2035. In product types, invasive ventilation is a major segment, while extracorporeal membrane oxygenation (ECMO), non-invasive ventilation, and oxygenators are also important components of the market.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/reports/artificial-lung-devices-market
Key Players
Xenios AG, Cleveland Heart, Terumo, Sorin Group, Getinge, Abbott Laboratories, Fresenius Medical Care, Medtronic, Asahi Kasei Medical, Toshiba Medical Systems Corporation, LivaNova, and Omni Life Science are among the companies profiled in the global Artificial Lung Devices Market.
Market Drivers and Trends
The increasing prevalence of respiratory disorders such as COPD and pulmonary fibrosis is a significant growth driver. The need for advanced respiratory support and organ-substitution technologies is encouraging healthcare providers to adopt sophisticated artificial lung systems.
Technological advancement is another major trend, with manufacturers focusing on miniaturization, enhanced biocompatibility, artificial intelligence, and improved monitoring capabilities. AI-assisted technologies can support real-time patient monitoring, device optimization, and earlier identification of potential complications.
The growing geriatric population is also strengthening demand because older adults face a higher risk of respiratory disorders and associated complications. At the same time, rising healthcare expenditure and investment in medical infrastructure are supporting the adoption of advanced respiratory technologies.
Market Segmentation
By product type, the market is segmented into Extracorporeal Membrane Oxygenation, Invasive Ventilation, Non-Invasive Ventilation, and Oxygenators. Invasive Ventilation was valued at approximately USD 700 million in 2024 and is projected to reach USD 1.4 billion by 2035.
By application, the market includes Cardiopulmonary Bypass, Respiratory Failure, Pulmonary Embolism, and Severe Pneumonia. Respiratory Failure and Cardiopulmonary Bypass represent important demand areas because of their role in critical care and advanced respiratory support.
By end user, the market is divided into Hospitals, Specialized Clinics, and Home Care Settings. Hospitals remain central to adoption because they provide critical-care and advanced respiratory treatment, while home care is gaining importance as healthcare delivery becomes more patient-centered.
By technology, the market comprises Hybrid Technology, Artificial Intelligence Assisted Technology, and Traditional Technology. AI-assisted solutions are gaining attention because they can improve device performance, patient monitoring, and predictive care capabilities.
Market Opportunities
The development of wearable and portable artificial lung technologies represents an important opportunity, potentially improving patient mobility and independence. Miniaturization and advances in biocompatible materials can further enhance device comfort and functionality.
AI-driven predictive analytics offers another opportunity by enabling real-time data analysis and proactive adjustments to respiratory support. Companies can also explore collaborations with biotechnology firms to develop hybrid systems that combine artificial lung technologies with regenerative medicine.
Emerging markets provide additional expansion opportunities as healthcare infrastructure improves and respiratory disease awareness increases. Regulatory expertise, home-care applications, and remote monitoring capabilities can help manufacturers broaden market access.
Recent Developments and Market Trends:
Terumo announced the acquisition of Xenios AG in June 2024, expanding its extracorporeal life-support portfolio and supporting the development of next-generation ECMO systems.
Getinge announced a strategic collaboration with Medtronic in November 2024 to co-develop next-generation ECMO circuits and integrated hospital software, highlighting the growing role of connected respiratory-support technologies.
Asahi Kasei Medical introduced a new membrane oxygenator in February 2025, reflecting continued product innovation within ECMO and artificial lung technologies.
Portable artificial lung devices are gaining traction because mobility and convenience are increasingly important for patients requiring longer-term organ support.
Remote monitoring and telemedicine integration are emerging as important trends, enabling artificial lung devices to provide clinicians with timely patient data and support more responsive treatment decisions.
Reasons to Buy the Report:
Understand the market size, forecast trajectory, growth rate, regional outlook, and competitive environment of the global Artificial Lung Devices Market.
Evaluate major product segments, including ECMO, invasive ventilation, non-invasive ventilation, and oxygenators, and identify areas of expanding demand.
Assess the impact of respiratory disease prevalence, aging demographics, technological advancement, and healthcare expenditure on future market growth.
Identify emerging opportunities in AI-assisted devices, wearable technologies, home healthcare, remote monitoring, and regenerative-medicine partnerships.
Gain competitive intelligence on leading companies, recent strategic developments, regional expansion prospects, and evolving technology trends shaping the industry.
Future Outlook
The Artificial Lung Devices Market is positioned for sustained expansion through 2035 as respiratory disease prevalence, population aging, healthcare investment, and technological innovation continue to increase demand. North America is expected to remain the leading regional market, while Asia-Pacific is positioned for significant expansion as healthcare access and investment improve.
Future development is likely to emphasize smaller and more portable devices, AI-assisted monitoring, improved biocompatibility, wearable technologies, and integration with telemedicine platforms. The market is projected to increase from USD 2.3 billion in 2025 to USD 4.5 billion by 2035 at a 7.1% CAGR.
